2 completed, 2 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
Follow ORIC-101: new trials by email Literature Review of ORIC-101 trials Research Report on ORIC-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ORIC-101 in Combination With Enzalutamide ORIC-101, enzalutamide 40 MG oral capsule [Xtandi] - Prostatic Neoplasms | Phase 1 | Terminated | ORIC Pharmaceuticals | 41 | 2019-10-28 | 2023-12-15 |
| Study of ORIC-101 in Combination With Anticancer Therapy ORIC-101, Nab-paclitaxel - Solid Tumor | Phase 1 | Terminated | ORIC Pharmaceuticals | 83 | 2019-05-02 | 2023-12-15 |
| Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects ORIC-101 - Healthy Volunteers | Phase 1 | Completed | ORIC Pharmaceuticals | 32 | 2018-03-23 | 2019-02-08 |
| Study of ORIC-101 in Healthy Adult Subjects ORIC-101 - Healthy Volunteers | Phase 1 | Completed | ORIC Pharmaceuticals | 24 | 2017-10-19 | 2018-04-05 |
United States (3) · United Kingdom (1)